SPG302 is a novel neuroprotective compound under development by Spinogenix, a biotech company focused on targets that preserve synaptic function and neuronal resilience in Alzheimer's disease and related neurodegenerative disorders. SPG302 is currently in Phase 1 clinical evaluation for mild-to-moderate Alzheimer's disease under NCT06427668.
| Attribute | Details |
|---|---|
| NCT Number | NCT06427668 |
| Phase | Phase 1 |
| Status | Active, not recruiting (as of 2026) |
| Sponsor | Spinogenix |
| Indication | Mild-to-moderate Alzheimer's disease |
| Mechanism | Neuroprotection (synaptic resilience, microtubule stabilization — see below) |
| Route | Oral (tablet) |
| Enrollment | Approximately 60 participants (estimated) |
Spinogenix is a clinical-stage biotech company dedicated to developing therapies that protect synapses and preserve neuronal function in Alzheimer's disease and other neurodegenerative conditions. The company is anchored by a novel mechanism targeting microtubule stabilization and synaptic resilience pathways[@spinogenix][@spinogenix_pipeline].
The company's scientific approach focuses on addressing the common downstream pathway of neurodegeneration — the disruption of synaptic integrity and axonal transport — rather than targeting upstream pathology-specific proteins like amyloid or tau. This mechanistic approach is designed to be disease-modifying across multiple neurodegenerative conditions.
Pipeline Programs:
While Spinogenix has not publicly disclosed the precise molecular target of SPG302, the company's scientific platform centers on microtubule stabilization and synaptic resilience[@vanelderen2024][@brunden2020]:
Microtubules are essential cytoskeletal structures that maintain neuronal architecture, support axonal transport, and enable synaptic signaling. In Alzheimer's disease, microtubule disruption is a hallmark feature:
Disease-Modifying Rationale: Unlike amyloid-targeting therapies that address upstream pathology, microtubule-stabilizing agents act on a common downstream convergence point shared by multiple neurodegenerative mechanisms. This positions them as potential disease-modifying therapies across diverse patient populations[@brunden2020].
Beyond microtubule stabilization, Spinogenix's approach encompasses synaptic resilience mechanisms[@moreno2023]:
| Program | Company | Target | Stage | Mechanism |
|---|---|---|---|---|
| SPG302 | Spinogenix | Microtubule/synaptic | Phase 1 | Microtubule stabilization |
| Davunetide | Allon Therapeutics | NPTX2 | Terminated | Synaptic protection |
| TauBx / BMS-986168 | Bristol-Myers Squibb | Microtubule | Discontinued | Epothilone D analog |
| Brevagen | Forward Pharma | Microtubule | Discontinued | Methylene blue derivative |
| Eptaflaren | Aptorum Group | Microtubule | Preclinical | Epothilone D analog |
The mild-to-moderate AD population represents a significant unmet medical need:
SPG302 is positioned to address the moderate AD population through:
Based on the NCT06427668 protocol and Spinogenix's published trial information:
The trial incorporates pharmacodynamic biomarkers consistent with Spinogenix's synaptic resilience platform:
| Biomarker | Target | Utility |
|---|---|---|
| CSF neurogranin | Synaptic integrity | Marker of synaptic health and treatment response |
| CSF NfL | Neuroaxonal injury | Monitoring disease progression and off-target effects |
| CSF total tau | Disease activity | Tracking neuronal stress response |
| CSF p-tau181 | Tau pathology | Confirming AD pathology status |
| CSF synaptic proteins | Synaptic function | Target engagement for SPG302 mechanism |
SPG302 operates at a downstream level of AD pathology, intersecting multiple mechanisms: